Sept. 18, 2018 Price forecast | 2 weeks: -0.15% | 1 month: 0.16% | 3 months: 0.58%


KPTI stock forecast

Our latest prediction for Karyopharm Therapeutics, Inc.'s stock price was made on the Sept. 18, 2018 when the stock price was at 18.57$.

In the short term (2weeks), KPTI's stock price should underperform the market by -0.15%. During that period the price should oscillate between -8.04% and +9.52%.

In the medium term (3months), KPTI's stock price should outperform the market by 0.58%. During that period the price should oscillate between -19.77% and +24.51%.


About Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

At the moment the company generates 30M USD in revenues.

On its last earning announcement, the company reported a loss of -3.14$ per share.

The book value per share is 3.52$

Karyopharm Therapeutics, Inc. website


Three months stock forecastSept. 18, 2018


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
30M - -180M -593.00% -178M -3.14 - - 57M 3.52 -159M -2M -161M